{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:28:43Z","timestamp":1790206123047,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Fifteen percent of patients with myasthenia gravis (MG) are refractory to conventional treatment. Case reports and a few studies show probable benefit of rituximab in these cases. Our objective was to assess the efficacy and the safety of rituximab in patients with MG, in a multicentric real\u2010life study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Inclusion criteria were: age &gt; 18\u00a0years; MG with anti\u2010acetylcholine receptor (AChR) antibodies, anti\u2010muscle\u2010specific kinase (MuSk) antibodies or significant decrement after repetitive nerve stimulation; Myasthenia Gravis Foundation of America (MGFA) class &gt;II; refractory or steroid\u2010dependent MG; and treatment with rituximab. Efficacy was assessed at 6\u00a0months using the MGFA\u2010post\u2010intervention status (PIS) score, the myasthenic muscle score (MMS) and the number of patients receiving steroids &lt;10\u00a0mg\/day. Data on adverse events were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010nine patients were included: 20 with anti\u2010AChR MG, five with anti\u2010MuSK MG and four with seronegative MG. MGFA\u2010PIS score was improved or better (improved, minimal manifestations or remission) in 86.2% of patients after 6\u00a0months of treatment (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001). The mean MMS increased from 68.8 to 83.1 (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001). A decrease in steroid dosage (&lt;10\u00a0mg\/day) was effective in 57.9% of treated patients. In all, 42.8% of patients experienced adverse events: infections (21.4% of patients); infusion reaction (7%); bradycardia (3.7%); and cytopenia (7%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present study demonstrates the efficacy and safety of rituximab in patients with MG. Additional studies remain necessary to determine the role of rituximab in the pharmacopeia of MG treatment and to establish precise recommendations for the infusion protocol.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.14391","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T20:43:52Z","timestamp":1591908232000},"page":"2277-2285","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real\u2010life study"],"prefix":"10.1111","volume":"27","author":[{"given":"A.","family":"Dos Santos","sequence":"first","affiliation":[{"name":"Department of Neurology University Hospital of Nantes Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. \u2010B.","family":"Noury","sequence":"additional","affiliation":[{"name":"Reference Centre for Neuromuscular Diseases AOC University Hospital of Brest Brest France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Genestet","sequence":"additional","affiliation":[{"name":"Reference Centre for Neuromuscular Diseases AOC University Hospital of Brest Brest France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nadaj\u2010Pakleza","sequence":"additional","affiliation":[{"name":"Reference Centre for Neuromuscular Diseases University Hospital of Strasbourg Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cassereau","sequence":"additional","affiliation":[{"name":"Reference Centre for Neuromuscular Diseases AOC University Hospital of Angers Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Baron","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurophysiology University Hospital of Poitiers Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Videt","sequence":"additional","affiliation":[{"name":"Department of Neurology Centre Hospitalier Bretagne Atlantique Vannes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Michel","sequence":"additional","affiliation":[{"name":"Department of Neurology University Hospital of Rennes Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Pereon","sequence":"additional","affiliation":[{"name":"Reference Centre for Neuromuscular Diseases AOC University Hospital of Nantes Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wiertlewski","sequence":"additional","affiliation":[{"name":"Department of Neurology University Hospital of Nantes Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Magot","sequence":"additional","affiliation":[{"name":"Reference Centre for Neuromuscular Diseases AOC University Hospital of Nantes Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410150316"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.08.057"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000034"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25973"},{"key":"e_1_2_7_8_1","unstructured":"Centre de r\u00e9f\u00e9rences de pathologie neuromusculaire Paris Est HAS.Protocole National de Diagnostic et de Soins (PNDS) Myasth\u00e9nie autoimmune.2015."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"key":"e_1_2_7_10_1","unstructured":"U.S. Department of health and human services.Common terminology criteria for adverse events (CTCAE) version 5.0.2017.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.564"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-319410"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09296-y"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.12.004"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21640"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25052"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.000"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982"},{"key":"e_1_2_7_19_1","first-page":"11","article-title":"Repeated low\u2010dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis","volume":"18","author":"Choi K","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7532-3"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.058"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.09.011"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90131-7"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004341"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.06.002"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000202"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.103"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00183-6"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.01.025"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.52.10.1121"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fene.14391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.14391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.14391","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.14391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T07:56:27Z","timestamp":1693814187000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.14391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,4]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/ene.14391"],"URL":"https:\/\/doi.org\/10.1111\/ene.14391","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,4]]},"assertion":[{"value":"2020-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}